EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo
Authors:
- 25 November 2015
- journal article
- retracted article
- Published by Spandidos Publications in Oncology Reports
- Vol. 35 (2) , 771-778
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 13 references indexed in Scilit:
- The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancerBreast Cancer, 2014
- Cancer treatment and survivorship statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyCancer and Metastasis Reviews, 2010
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesCancer, 2010
- SATB1 reprogrammes gene expression to promote breast tumour growth and metastasisNature, 2008
- Up‐regulation of CD147 and matrix metalloproteinase‐2, ‐9 induced by P‐glycoprotein substrates in multidrug resistant breast cancer cellsCancer Science, 2007
- Involvement of CD147 in regulation of multidrug resistance to P‐gp substrate drugs andin vitroinvasion in breast cancer cellsCancer Science, 2007
- P-glycoprotein: from genomics to mechanismOncogene, 2003
- Treatment of Multidrug Resistant (MDR1) Murine Leukemia with P-Glycoprotein Substrates Accelerates the Course of the DiseaseBiochemical and Biophysical Research Communications, 1999
- P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulationMolecular Aspects of Medicine, 1995